ADMA:NSD-ADMA Biologics Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 19.74

Change

+0.42 (+2.17)%

Market Cap

USD 4.60B

Volume

5.49M

Analyst Target

USD 9.83
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey. Address: 465 State Route 17, Ramsey, NJ, United States, 07446

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-19 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
REGN Regeneron Pharmaceuticals Inc

+11.38 (+1.00%)

USD 127.14B
VRTX Vertex Pharmaceuticals Inc

+3.74 (+0.79%)

USD 125.27B
ALNY Alnylam Pharmaceuticals Inc

+3.18 (+1.16%)

USD 35.07B
ARGX argenx NV ADR

+7.28 (+1.38%)

USD 32.07B
MRNA Moderna Inc

-1.84 (-2.63%)

USD 26.25B
SMMT Summit Therapeutics PLC

-1.40 (-5.70%)

USD 23.47B
BGNE BeiGene Ltd

+1.31 (+0.66%)

USD 21.94B
RPRX Royalty Pharma Plc

-0.22 (-0.78%)

USD 16.45B
BMRN Biomarin Pharmaceutical Inc

+0.27 (+0.38%)

USD 16.16B
UTHR United Therapeutics Corporatio..

+8.74 (+2.55%)

USD 15.09B

ETFs Containing ADMA

PTH Invesco DWA Healthcare Mo.. 4.14 % 0.60 %

+1.01 (+1.81%)

USD 0.15B
ISMD Inspire Small/Mid Cap Imp.. 0.30 % 0.62 %

+0.68 (+1.81%)

USD 0.19B
BBP Virtus LifeSci Biotech Pr.. 0.00 % 0.79 %

+0.87 (+1.81%)

USD 0.02B
FYC First Trust Small Cap Gro.. 0.00 % 0.70 %

+1.43 (+1.81%)

USD 0.32B
FYX First Trust Small Cap Cor.. 0.00 % 0.63 %

+1.83 (+1.81%)

USD 0.91B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 336.73% 98% N/A 99% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 336.73% 97% N/A 99% N/A
Trailing 12 Months  
Capital Gain 454.49% 98% N/A 99% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 454.49% 98% N/A 99% N/A
Trailing 5 Years  
Capital Gain 271.05% 92% A 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 271.05% 91% A- 93% A
Average Annual (5 Year Horizon)  
Capital Gain 42.53% 83% B 88% B+
Dividend Return 42.53% 83% B 88% B+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 87.92% 36% F 20% F
Risk Adjusted Return 48.37% 94% A 78% C+
Market Capitalization 4.60B 95% A 87% B+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.